Business Wire

Huawei ICT Academy Advisory Board Leads the Way in Securing the ICT Talent Ecosystem for the Future

Share

There is a crisis emerging in the ICT industry, as the sector struggles to fill vital roles. Talent supply is the top problem facing digital tech businesses in the UK, according to Technation. As technology evolves, experienced staff retire, and more jobs become available, this problem is set to get worse. In fact, there are predicted to be 1.7 million new ICT jobs for tech specialists between 2015 and 2025, and candidates need the skills and experience to fill them.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180508005796/en/

Professor Zhili Sun, Vice-Chair Academia of the Huawei ICT Academy Advisory Board (Photo: Business W ...

Professor Zhili Sun, Vice-Chair Academia of the Huawei ICT Academy Advisory Board (Photo: Business Wire)

To help solve this problem, Huawei ICT Academy provides a not-for-profit education initiative that facilitates partnerships between universities and business, supporting young Europeans with great potential in digital, such as students, developers and entrepreneurs. The Huawei ICT Academy Advisory Board was established in November 2017 to lead the Huawei ICT Academy in Western Europe and runs independently, supported by investment from Huawei. It is Huawei’s only association of this type outside China. The Board leads the overall direction and development of the Huawei ICT Academy and supports the industry in furthering practitioner knowledge.

The Huawei ICT Academy Advisory Board is made up of renowned academics, members of professional bodies and leaders from Huawei. It ensures that the Huawei ICT Academy provides a platform for academic excellence and challenges students and developers with competitions and certifications, helping its audience of New Young Europeans to have successful ICT roles in the future.

Professor Zhili Sun, Vice-Chair Academia of the Huawei ICT Academy Advisory Board, and professor of Communication Networking at the University of Surrey, said: “We set up a committee to serve the group of young talented people involved in skills within the UK and Europe.”

The board is led by Professor Edmund Burke, Chair – Academia and Vice Principal for Science and Engineering at Queen Mary University, London. His Co-Chair is Mr. Bradd Feng, Director of Global Training and Certification Dept. at Huawei. Together they lead the 20 board members who oversee the Huawei ICT Academy’s programs, processes, delivery and organization and lead on the strategic development of the Huawei ICT Academy Program in the UK.

For example, Huawei and Huawei ICT Academy organise the Huawei ICT Skill Competition to develop ICT professionals, connecting with the makers and doers of the digital future. The global final of the competition takes place in China in May, with six students from Western Europe competing. They will learn relevant skills and gain experience that will power the entire industry and, ultimately, drive digital transformation. Huawei also works with governments, offers globally recognised certifications, graduate programs and joint R&D projects to help build an open, sustainable ICT ecosystem.

By bringing together leaders from academia and industry, the Advisory Board’s leadership will further the development of the ICT Industry by providing advice on issues of strategic importance, such as the syllabus, virtual learning resources, program delivery and processes. Technology advances come rapidly in the ICT sector, so by overseeing the direction of the ICT Academy Programme, the Advisory Board ensures that students are developing vital knowledge to become a new type of multi-skilled engineer – critical to the ICT industry as well as to global development and growth.

This will continue to have a positive impact when students enter the workplace. Pearson VUE’s 2017 Value of Certification Survey found that 54% of people experienced their first benefit within three months of gaining a certification, such as a salary increase or promotion. Additionally, 93% of hiring managers recognise industry certifications.

Huawei ICT Academy
Huawei ICT Academy is a not-for-profit education program that facilitates university-enterprise partnerships. The project aims to lead ICT development, build the future of the ICT industry, and create a sound talent ecosystem by providing ICT education worldwide. To date, Huawei has fostered cooperation with more than 300 universities in Europe, North America, Southeast Asia, Australia, and other regions around the world. In the future, Huawei will hold higher education development summit forums and forge ICT talent alliances to further drive the healthy, sustainable, and efficient development of the ICT talent ecosystem.
www.huaweiacad.com

Contact information

Huawei ICT Academy
Pallavi Malhotra
Manager
pallavi.malhotra@huawei.com
00447833082979

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications23.7.2019 06:30:00 CESTPress release

Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the

iBASIS Accelerates Growth With JC Geha as Chief Operating Officer23.7.2019 06:00:00 CESTPress release

iBASIS, provider of communications solutions for operators and digital players worldwide, today announced the appointment of JC Geha as its COO. He will take his new post effective August 1, and be based at iBASIS’ headquarters in Lexington, Massachusetts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005757/en/ JC Geha (Photo: Business Wire) Formerly Senior Vice President, Head of International Technology and Services for Deutsche Telekom, and of Managed Services for Ericsson, Geha brings to iBASIS an impressive track record of profitable growth, technology and digital transformation expertise. His expertise spans 25 years of deep global industry relationships across the United States, Europe, Middle East, and Africa. Geha will lead iBASIS’ global operations, engineering, IT, and product development. He will report to iBASIS’ CEO and founder of the Group Tofane Global, Alexandre Pébereau, with the responsibility of g

Abzena Announces Successful Technical Transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) Technology to Enable Use in Client Projects23.7.2019 06:00:00 CESTPress release

Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). Familiarity with these Antibody-Drug Conjugate (ADC) technologies adds to Abzena’s leadership in process development and GMP manufacturing of ADC linkers and payloads. Abzena can now rapidly ramp up ADC projects using Synaffix technology with high scientific quality. Jonathan Goldman, MD, Abzena CEO added: “Abzena believes in patient first drug development. Our expertise and experience with Synaffix GlycoConnect™ and HydraSpace™ technology further advances our leadership across multiple platforms in ADC. We look forward to supporting our customers as they leverage Synaffix technology to rapidly advance ADCs from IND stage into early clinical development.” About Abzena Abzena provides the most complete set of solutions in integrated discover

Aroma Bit to Develop Smartphone Embeddable Ultra-compact Silicon CMOS Based Smell Sensor That Has Dog Nose Equivalent Resolution in 1mm Squared Die Size23.7.2019 01:30:00 CESTPress release

Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/ Picture of 1mm squared die of silicon CMOS based smell sensor, with dog nose equivalent ~1,200 sensor pixels (Photo: Business Wire) Aroma Bit: http://www.aromabit.com Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Micro

Logitech Delivers a Strong Start to Fiscal Year 2020 with Robust Sales and Profit Growth23.7.2019 01:00:00 CESTPress release

Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the first quarter of Fiscal Year 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005781/en/ Logitech delivers a strong start to Fiscal Year 2020 with robust sales and profit growth. (Graphic: Business Wire) Q1 sales were $644 million, up 6 percent in US dollars and 9 percent in constant currency, compared to Q1 of the prior year. Q1 GAAP operating income grew 46 percent to $47 million, compared to $32 million in the same quarter a year ago. Q1 GAAP earnings per share (EPS) grew 17 percent to $0.27, compared to $0.23 in the same quarter a year ago. Q1 non-GAAP operating income grew 11 percent to $67 million, compared to $61 million in the same quarter a year ago. Q1 non-GAAP EPS grew 15 percent to $0.39, compared to $0.34 in the same quarter a year ago. Cash flow from operations was $37 million, compared to $12 million in the sa

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 16:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an